Skip to main content

Skye Bioscience Inc

For the period ended Dec 31, 2023. Filed Mar 22, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 22, 2024

SKYE$0.69-30.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

PAGE
PART I
Item 1.Business4
Item 1A.Risk Factors16
Item 1B.Unresolved Staff Comments54
Item 1C.Cybersecurity54
Item 2.Properties55
Item 3.Legal Proceedings55
Item 4.Mine Safety Disclosures55
PART II
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities56
Item 6.Selected Financial Data56
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations56
Item 7A.Quantitative and Qualitative Disclosures About Market Risk63
Item 8.Financial Statements and Supplementary Data63
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure63
Item 9A.Controls and Procedures63
Item 9B.Other Information64
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections48
PART III
Item 10.Directors, Executive Officers and Corporate Governance65
Item 11.Executive Compensation71
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters76
Item 13.Certain Relationships and Related Transactions, and Director Independence79
Item 14.Principal Accountant Fees and Services81
PART IV
Item 15.Exhibits, Financial Statement Schedules83
Signatures
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.